Skip to content
zameds

Zolmitriptan

Sold as Zomig, Zomig rapimelt, Zomig nasal, Zograine, Zograine rapimelt, Zolmifor odt, Zolmifor, Mizyga fc, Mizyga odt

S4Read from the PI-PIL document and verified
Loading the molecular structure
C16H21N3O2287.36 g/mol

(4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one

Drag to rotate. Structure from PubChem CID 60857.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
6
Registrations
10
Schedule source
SAHPRA documentation

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Adcock ingram limitedCertificate held by Astrazeneca Pharmaceuticals (Pty) LtdZomig, Zomig rapimelt2,5320478, 340107S4PIPIL
Astrazeneca Pharmaceuticals (Pty) LtdCancelledZomig, Zomig nasal5, spray320479, 360133S4PIPIL
Pharmaplan (Pty) LtdZograineNot stated451069S4None
Acino Pharma (Pty) LtdZograine rapimeltNot stated451070S4None
Jubilant Pharma SA (Pty) LtdZolmifor odt, ZolmiforNot stated451119, 451120S4None
Macleods Pharmaceuticals SA (Pty) LtdCancelledMizyga fc, Mizyga odt2.5mg, 2.5 mg470751, 470821S4None

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Zomig 2,5

EACH TABLET CONTAINS ZOLMITRIPTAN 2,5 mg

2,5Tablets32047832/7.3/0478Approved 29 June 2015RegisteredS4PIPIL
Zomig 5

EACH TABLET CONTAINS ZOLMITRIPTAN 5 mg

5Tablets32047932/7.3/0479Approved 29 June 2015CancelledS4PIPIL
Zomig rapimelt

EACH DISPERSIBLE TABLET CONTAINS ZOLMITRIPTAN 2,5 mg

Not listed34010734/7.3/0107RegisteredS4None
Zomig nasal spray

EACH 1,0 ml SOLUTION CONTAINS: ZOLMITRIPTAN 50,0 mg

Spray36013336/7.3/0133CancelledS4None
Zograine

EACH TABLET CONTAINS ZOLMITRIPTAN 2,5 mg

Not listed45106945/7.3/1069RegisteredS4None
Zograine rapimelt

EACH TABLET CONTAINS ZOLMITRIPTAN 2,5 mg

Not listed45107045/7.3/1070RegisteredS4None
Zolmifor odt

EACH TABLET CONTAINS : ZOLMITRIPTAN 2,5 mg

Not listed45111945/7.3/1119RegisteredS4None
Zolmifor

EACH TABLET CONTAINS : ZOLMITRIPTAN 2,5 mg

Not listed45112045/7.3/1120RegisteredS4None
Mizyga 2.5mg fc tablets

EACH TABLET CONTAINS: ZOLMITRIPTAN 2,5 mg

2.5mgTablets47075147/7.3/0751CancelledS4None
Mizyga odt 2.5 MG

EACH TABLET CONTAINS: ZOLMITRIPTAN 2,5 mg

2.5 mg47082147/7.3/0821CancelledS4None

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, read from the product's PI-PIL leaflet.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Zolmitriptan

  • S4: Zolmitriptan

    Consolidated Schedules 06 July 2026, line 8420

Pharmacological class: Migraine preparations. (class 7.3)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Zomig 2,5, Adcock ingram limited is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsZomig 2,5, Adcock ingram limitedPatient information leaflet (PIL)For patients and carersZomig 2,5, Adcock ingram limited

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles